GW6471

€98.00

Excl. VAT

Item no.	HY-15372-10mg
Manufacturer	MedChem Express
CASRN	880635-03-0
Amount	10 mg
Category	Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.81
Formula	C35H36F3N3O4
Citations	[1]Xu HE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature. 2002 Feb 14;415(6873):813-7. [2]Abu Aboud O, et al. Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysisinhibition in kidney cancer cells. PLoS One. 2013 Aug 7;8(8):e71115. [3]Abu Aboud O, et al. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8.
Smiles	CCC(NC[C@@H](N/C(C)=C\C(C1=CC=C(C(F)(F)F)C=C1)=O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	880635-03-0
Available
Product Description	GW6471 is a potent PPARα antagonist.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
Molecular Weight	619.67
Clinical Information	No Development Reported
Solubility	DMSO : 83.33 mg/mL (ultrasonic; warming; heat to 60°C)
Isoform	PPARα
Pathway	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15372-10mg-safety-datasheet.pdf